厄贝沙坦自微乳化给药系统(SMEDDS)的配方开发、统计优化及表征

S. Swain, P. K. Sahu, B. R. Jena, S. Beg, S. M. Babu
{"title":"厄贝沙坦自微乳化给药系统(SMEDDS)的配方开发、统计优化及表征","authors":"S. Swain, P. K. Sahu, B. R. Jena, S. Beg, S. M. Babu","doi":"10.2174/2210681208666180125143258","DOIUrl":null,"url":null,"abstract":"\n\n Irbesartan is an anti-hypertensive BCS class II drug exhibiting poor aqueous\nsolubility, which makes it highly challenging for delivery through the oral route. Based on this fact, a\nself-microemulsifying drug delivery system (SMEDDS) was designed and characterized for augmenting\nthe aqueous solubility and dissolution rate of irbesartan.\n\n\n\nSeveral blends of oil (Capmul MCM EP), surfactant (Tween 80) and co-surfactant (PEG 600)\nwere screened from the preliminary solubility and pseudo-ternary phase diagram studies. Systematic optimization\nof the SMEDDS was carried out using 3-factor 3-level Box-Behnken design.\n\n\n\nThe optimized formulation was identified by numerical optimization technique, which revealed\nfaster emulsification time, high percent transmittance and drug content, lower globule size < 100 nm,\nzeta potential and excellent thermodynamic stability. The optimal formulation unveiled more than\n93.3% drug release in vitro within 60 minutes, while the pure drug exhibited only 20% drug release, respectively.\n\n\n\nEx vivo permeability and in situ intestinal absorption of drugs was improved nearly 2 to 3-\nfold by the optimal SMEDDS formulation against the pure drug alone (p < 0.001). Overall, the proposed\nSMEDDS formulation of irbesartan exhibited a superior biopharmaceutical performance.\n","PeriodicalId":18979,"journal":{"name":"Nanoscience & Nanotechnology-Asia","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Formulation Development, Statistical Optimization and Characterization of the Self-Microemulsifying Drug Delivery System (SMEDDS) of Irbesartan\",\"authors\":\"S. Swain, P. K. Sahu, B. R. Jena, S. Beg, S. M. Babu\",\"doi\":\"10.2174/2210681208666180125143258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\n Irbesartan is an anti-hypertensive BCS class II drug exhibiting poor aqueous\\nsolubility, which makes it highly challenging for delivery through the oral route. Based on this fact, a\\nself-microemulsifying drug delivery system (SMEDDS) was designed and characterized for augmenting\\nthe aqueous solubility and dissolution rate of irbesartan.\\n\\n\\n\\nSeveral blends of oil (Capmul MCM EP), surfactant (Tween 80) and co-surfactant (PEG 600)\\nwere screened from the preliminary solubility and pseudo-ternary phase diagram studies. Systematic optimization\\nof the SMEDDS was carried out using 3-factor 3-level Box-Behnken design.\\n\\n\\n\\nThe optimized formulation was identified by numerical optimization technique, which revealed\\nfaster emulsification time, high percent transmittance and drug content, lower globule size < 100 nm,\\nzeta potential and excellent thermodynamic stability. The optimal formulation unveiled more than\\n93.3% drug release in vitro within 60 minutes, while the pure drug exhibited only 20% drug release, respectively.\\n\\n\\n\\nEx vivo permeability and in situ intestinal absorption of drugs was improved nearly 2 to 3-\\nfold by the optimal SMEDDS formulation against the pure drug alone (p < 0.001). Overall, the proposed\\nSMEDDS formulation of irbesartan exhibited a superior biopharmaceutical performance.\\n\",\"PeriodicalId\":18979,\"journal\":{\"name\":\"Nanoscience & Nanotechnology-Asia\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanoscience & Nanotechnology-Asia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2210681208666180125143258\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanoscience & Nanotechnology-Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210681208666180125143258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

厄贝沙坦是一种抗高血压的BCS II类药物,具有较差的水溶性,这使得通过口服途径给药极具挑战性。在此基础上,设计了提高厄贝沙坦溶解度和溶出率的自微乳化给药系统。从初步溶解度和拟三元相图研究中筛选出了几种油(Capmul MCM EP)、表面活性剂(Tween 80)和助表面活性剂(PEG 600)的共混物。采用3因素3水平Box-Behnken设计对SMEDDS进行了系统优化。优化后的配方乳化时间短,透光率高,药物含量高,粒径< 100 nm,zeta电位小,热力学稳定性好。最优处方60分钟体外释药率达93.3%以上,纯药60分钟体外释药率仅为20%。与纯药物相比,最佳SMEDDS配方可使药物的体外通透性和原位肠道吸收提高近2 ~ 3倍(p < 0.001)。总体而言,所提出的厄贝沙坦dsmedds制剂表现出优越的生物制药性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Formulation Development, Statistical Optimization and Characterization of the Self-Microemulsifying Drug Delivery System (SMEDDS) of Irbesartan
Irbesartan is an anti-hypertensive BCS class II drug exhibiting poor aqueous solubility, which makes it highly challenging for delivery through the oral route. Based on this fact, a self-microemulsifying drug delivery system (SMEDDS) was designed and characterized for augmenting the aqueous solubility and dissolution rate of irbesartan. Several blends of oil (Capmul MCM EP), surfactant (Tween 80) and co-surfactant (PEG 600) were screened from the preliminary solubility and pseudo-ternary phase diagram studies. Systematic optimization of the SMEDDS was carried out using 3-factor 3-level Box-Behnken design. The optimized formulation was identified by numerical optimization technique, which revealed faster emulsification time, high percent transmittance and drug content, lower globule size < 100 nm, zeta potential and excellent thermodynamic stability. The optimal formulation unveiled more than 93.3% drug release in vitro within 60 minutes, while the pure drug exhibited only 20% drug release, respectively. Ex vivo permeability and in situ intestinal absorption of drugs was improved nearly 2 to 3- fold by the optimal SMEDDS formulation against the pure drug alone (p < 0.001). Overall, the proposed SMEDDS formulation of irbesartan exhibited a superior biopharmaceutical performance.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信